bioMérieux has released a groundbreaking international economic analysis demonstrating that early use of rapid identification and antibiotic susceptibility tests (ID/AST) can significantly reduce avoidable cases of sepsis among high-risk bloodstream infection patients. Conducted by the Office of Health Economics (OHE), this study is the first to consistently show across multiple healthcare systems—including those in Canada, France, Germany, Italy, Japan, the UK, and the US—that rapid diagnostics can improve clinical outcomes and generate substantial cost savings.

The analysis highlights that sepsis is a leading cause of preventable death, responsible for nearly 21 million fatalities globally each year. The timely administration of targeted antibiotics is critical for survival, yet traditional diagnostic methods often delay results by 2-3 days, leading to inappropriate initial treatments in about 20% of cases. By integrating rapid ID/AST at the onset of care, the study found that the incidence of sepsis could decrease by over 20%, resulting in lower mortality rates and fewer long-term complications, thereby enhancing patient quality of life.

This analysis underscores the urgent need to reform healthcare policies regarding diagnostics. Currently, diagnostics are undervalued within healthcare expenditure frameworks, often treated as costs rather than as essential value drivers. The findings suggest that implementing rapid ID/AST could save approximately $1,000 per patient in Canada alone, translating to nearly $42 million in annual savings. This evidence provides a compelling case for policymakers to reevaluate how diagnostics are funded and integrated into clinical pathways, ultimately aiming to improve patient outcomes and optimize healthcare resource allocation.

Source: globenewswire.com